Tandutinib is primarily used in research and clinical settings as an inhibitor targeting specific tyrosine kinases, particularly FLT3, c-KIT, and PDGFR. Its application is most notable in the study and treatment of acute myeloid leukemia (AML), where FLT3 mutations are commonly observed. By inhibiting FLT3, tandutinib helps to block the signaling pathways that promote the growth and survival of leukemic cells. This makes it a potential therapeutic option for patients with FLT3-mutated AML. Additionally, its activity against c-KIT and PDGFR has led to its exploration in other cancers, such as gastrointestinal stromal tumors (GISTs) and certain types of sarcomas, where these receptors play a role in tumor progression. Tandutinib is also used in preclinical studies to better understand the mechanisms of tyrosine kinase signaling and its impact on cancer cell behavior.